Docoh
Loading...

ENTX Entera Bio

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.

ENTX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

18 Mar 21
17 Oct 21
31 Dec 21
Quarter (USD)
Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Entera Bio earnings reports.

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

31.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 19 10 +90.0%
Opened positions 12 8 +50.0%
Closed positions 3 0 NEW
Increased positions 2 0 NEW
Reduced positions 3 0 NEW
13F shares
Current Prev Q Change
Total value 33.19M 10.03M +230.9%
Total shares 7.55M 4.26M +77.0%
Total puts 210.5K 0 NEW
Total calls 271.7K 0 NEW
Total put/call ratio 0.8
Largest owners
Shares Value Change
Knoll Capital Management 2.48M $14.86M +38.7%
Ra Capital Management 2.35M $14.07M NEW
Capital Point 1.15M $1.24M 0.0%
Centillion Fund 1.13M $1.22M 0.0%
Ionic Capital Management 113.43K $113K NEW
Citadel Advisors 67.17K $402K NEW
Susquehanna International 66.73K $399K NEW
Warberg Asset Management 45K $45K NEW
Millennium Management 34.78K $208K -9.9%
Verition Fund Management 30.52K $183K NEW
Largest transactions
Shares Bought/sold Change
Ra Capital Management 2.35M +2.35M NEW
Knoll Capital Management 2.48M +692.91K +38.7%
Renaissance Technologies 0 -120.41K EXIT
Ionic Capital Management 113.43K +113.43K NEW
Citadel Advisors 67.17K +67.17K NEW
Susquehanna International 66.73K +66.73K NEW
Warberg Asset Management 45K +45K NEW
Verition Fund Management 30.52K +30.52K NEW
Geode Capital Management 17.6K +17.6K NEW
Simplex Trading 15.74K +15.74K NEW

Financial report summary

?
Competition
AMGENShireChugai Pharmaceutical
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg

Proxies

No filings